0.41%| Prev Close: | 5.27 |
|---|---|
| Open: | 5.16 |
| Bid: | 4.30 x 1000 |
| Ask: | 5.74 x 100 |
| 1y Target Est: | 8.64 |
| Beta: | N/A |
| Next Earnings Date: | N/A |
| Day's Range: | 4.78 - 5.30 |
|---|---|
| 52wk Range: | 4.78 - 11.00 |
| Volume: | 16,779,570 |
| Avg Vol (3m): | 4,939,980 |
| Market Cap: | 1.12B |
| P/E (ttm): | N/A |
| EPS (ttm): | N/A |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Credit Suisse Lowers Price Target On Arena, What's Next?at Seeking Alpha(Mon, Sep 30)
- Comcast Readies Bid for Houston Astros Carrier and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Mon, Sep 30)
- Will Arena Be Able To Write A Growth Story?at Seeking Alpha(Mon, Sep 30)
- Arena Pharma falls after analyst cuts outlookAP(Mon, Sep 30)
- Valuing the Next Obesity Drugmakerat Motley Fool(Mon, Sep 30)
- Arena Pharmaceuticals price target lowered to $4 from $5 at Credit Suissetheflyonthewall.com(Mon, Sep 30)
- For Arena, Belviq Refills Are Becoming Keyat Seeking Alpha(Sat, Sep 28)
- First Week of December 21st Options Trading For Arena Pharmaceuticals (ARNA)at Forbes(Fri, Sep 27)
- Arena Sales - Pacing Along Modestlyat Seeking Alpha(Fri, Sep 27)
- What's Weighing on Obesity Drug Makers Vivus and Arena?at Minyanville(Thu, Sep 26)
- Biotech Investors: Be Careful Who You Listen Toat Motley Fool(Thu, Sep 26)
- VIVUS' Hopes Tied to QsymiaZacks(Wed, Sep 25)
- When the EMA Says No, Try, Try, and Try Againat Motley Fool(Tue, Sep 24)
- Novo Nordisk Advertising Weight Loss - A Future Peak At Arena Or Vivus?at Seeking Alpha(Tue, Sep 24)
- Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry ConferencePR Newswire(Mon, Sep 23)
Press Releases
- Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry ConferencePR Newswire(Mon, Sep 23)
- Arena Pharmaceuticals to Present Clinical Data for BELVIQ® (lorcaserin HCl) CIV at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)PR Newswire(Wed, Sep 18)
- Arena Pharmaceuticals Provides Update as Eisai's Launch of BELVIQ® (lorcaserin HCl) CIV Enters Consumer PhasePR Newswire(Mon, Sep 16)
Reports
- Wright Investors Service Comprehensive Report for Arena Pharmaceuticals, Inc.Wright Reports(Oct 1)
- ARNA: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Oct 1)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(Oct 1)